- Home
- PTGX vs MIRM Comparison
PTGX vs MIRM Comparison
Compare PTGX & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PTGX | MIRM |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 5.7B |
| IPO Year | 2016 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PTGX | MIRM |
|---|---|---|
| Price | $121.88 | $123.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 13 |
| Target Price | $108.23 | ★ $119.85 |
| AVG Volume (30 Days) | 705.9K | ★ 785.1K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | ★ $19,138,000.00 |
| Revenue This Year | $874.25 | $26.22 |
| Revenue Next Year | N/A | $22.04 |
| P/E Ratio | $2,455.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $49.86 | $47.89 |
| 52 Week High | $126.25 | $119.49 |
Technical Indicators
Market Signals| Indicator | PTGX | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 66.64 | 78.30 |
| Support Level | $94.48 | $87.93 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 4.67 | 4.98 |
| MACD | 1.54 | 2.49 |
| Stochastic Oscillator | 77.87 | 92.80 |
Price Performance
Historical ComparisonAbout PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.